Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DA-5212
- Development stage
- Phase 3
- Lead developer
- Dong-A ST
- Modality
- Small Molecules
01
Overview
DA-5212 is a small molecule drug developed by Dong-A ST for the treatment of functional dyspepsia and other digestive system disorders. Its mechanism of action involves inhibition of specific enzymes and signaling pathways that are crucial for cancer cell growth and survival, although in clinical development it has been primarily studied for gastrointestinal indications such as functional dyspepsia. Unlike traditional chemotherapy, which can affect both healthy and malignant cells, DA-5212 aims to selectively target pathological processes[1][4]. The drug has completed Phase 3 clinical trials in patients with functional dyspepsia[2][3][4].
Beyond the preview
Go deeper on DA-5212.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DA-5212.